Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis.

Background: The US National Cancer Institute alert in February, 1999, stated that concomitant chemotherapy and radiotherapy should be considered for all patients with cervical cancer. Our aim was to review the effects of chemoradiotherapy on overall and progression-free survival, local and distant c...

Descripción completa

Detalles Bibliográficos
Publicado en:Lancet Vol. 358; no. 9284; pp. 781 - 787
Autores principales: Green, John A, Kirwan, John M, Tierney, Jayne F, Symonds, Paul, Fresco, Lydia, Collingwood, Mandy, Williams, Christopher J, Green, J A, Kirwan, J M, Tierney, J F, Symonds, P, Fresco, L, Collingwood, M, Williams, C J
Formato: meta analysis research Journal Article
Publicado: Lancet 9/8/2001
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=5150599&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 5150599
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01406736
        LAN
      jtl: Lancet
      issn: 01406736
      maglogo: N
    pubinfo:
      dt: 9/8/2001
      vid: 358
      iid: 9284
      pid: 1297
      pub: Lancet
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        5150599
        5150599
        NLM11564482
        5150599
        10.1016/S0140-6736(01)05965-7
        NLM11564482
        5150599
      ppf: 781
      ppct: 6
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: C
          – @attributes:
              type: P
      tig:
        atl: Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis.
      aug:
        au:
          Green, John A
          Kirwan, John M
          Tierney, Jayne F
          Symonds, Paul
          Fresco, Lydia
          Collingwood, Mandy
          Williams, Christopher J
          Green, J A
          Kirwan, J M
          Tierney, J F
          Symonds, P
          Fresco, L
          Collingwood, M
          Williams, C J
        affil: Department of Medicine, University of Liverpool, L69 3GA, Liverpool, UK
      sug:
        subj:
          Cervix Neoplasms Radiotherapy
          Cervix Neoplasms Mortality
          Cervix Neoplasms Drug Therapy
          Antineoplastic Agents Therapeutic Use
          Human
          Survival
          Medical Practice, Evidence-Based
          Neoplasm Recurrence, Local
          Female
          Antineoplastic Agents Adverse Effects
          Clinical Trials
          Meta Analysis
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
          Female
      ab: Background: The US National Cancer Institute alert in February, 1999, stated that concomitant chemotherapy and radiotherapy should be considered for all patients with cervical cancer. Our aim was to review the effects of chemoradiotherapy on overall and progression-free survival, local and distant control, and acute and late toxicity in patients with cervical cancer.Methods: With the methodology of the Cochrane Collaboration, we did a systematic review of all known randomised controlled trials done between 1981 and 2000 (17 published, two unpublished) of chemoradiation for cervical cancer.Findings: The trials included 4580 randomised patients, and 2865-3611 patients (62-78%) were available for analysis. Cisplatin was the most common agent used. The findings suggest that chemoradiation improves overall survival (hazard ratio 0.71, p<0.0001), whether platinum was used (0.70, p<0.0001) or not (0.81, p=0.20). A greater beneficial effect was seen in trials that included a high proportion of stage I and II patients (p=0.009). An improvement in progression-free survival was also seen with chemoradiation (0.61, p<0.0001). Thus, the absolute benefit in progression-free and overall survival was 16% (95% CI 13-19) and 12% (8-16), respectively. A significant benefit of chemoradiation on both local (odds ratio 0.61, p<0.0001) and distant recurrence (0.57, p<0.0001) was also recorded. Grade 3 or 4 haematological (odds ratio 1.49-8.60) and gastrointestinal (2.22) toxicities were significantly greater in the concomitant chemoradiation group than the control group. There was insufficient data to establish whether late toxicity was increased in the concomitant chemoradiation group.Interpretation: Concomitant chemotherapy and radiotherapy improves overall and progression-free survival and reduces local and distant recurrence in selected patients with cervical cancer, which may give a cytotoxic and sensitisation effect.
      pubtype: Academic Journal
      doctype:
        meta analysis
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N